// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Clinical efficacy and safety profile of allergen‐specific immunotherapy using microcrystalline tyrosine (MCT)‐adsorbed allergoids – A meta‐analysis

Becker S - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

L-Tyrosine

The role of interferon type I and type III receptors in rhinovirus induced allergic asthma

Krug J - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Interferon

Polyethylene glycol is the major allergen in depot medroxyprogesterone acetate (DMPA)

Lu IN - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

Medroxyprogesterone

A fungal spore calendar for England: Analysis of 13 years of daily counts at Leicester, UK

Pashley CH - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Twin-reversed arterial perfusion

N/A

Current allergy educational needs in primary care. Preliminary results of the EAACI working group on primary care survey

Cabrera M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

“whole” vs “fragmented” approach to EAACI pollen season definitions: A multicenter study in six Southern European cities

Hoffmann TM - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Nonadherence to carrying and using adrenaline pens in adults with anaphylaxis: The impact of a theoretically informed training intervention on staff knowledge and beliefs

Mahoney B - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

Epinephrine

Development and implementation of a nurse‐led allergy clinic model in primary care: A feasibility trial

Kelman ME - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Allergic rhinitis

N/A

Written emotional disclosure in adults with asthma: How does the nature of the experience disclosed effect outcomes?

Hazell C - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Asthma

N/A

A heligmosomoides polygyrus‐induced serum‐borne factor promotes monocytosis and protects against respiratory syncytial virus infection in the lung

Burgess M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prevalence and impact on care of contrast allergy amongst acute vascular admissions; a pilot study

Rinaldi G - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Parental perspectives on clinical and research needs in food protein‐induced enterocolitis syndrome (FPIES)

Meyer J - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Enterocolitis

N/A

Differences in epitome response in peanut‐allergic subjects treated with different immunotherapy preparations

Kearney P - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Early clinical development plan for a novel virus like particle displaying Ara h 2 for the subcutaneous treatment of peanut allergy

Oluwayi K - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Understanding parent preferences for paediatric allergy services

Diwakar L - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Early introduction of peanut reduces peanut allergy across different risk groups: Results from pooled and causal inference analyses

Logan K - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Avapritinib reduced cutaneous symptoms and mast cell (MC) burden in patients (pts) with indolent systemic mastocytosis (ISM) in the PIONEER study

Hartmann K - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Mastocytosis

N/A

Metabolome‐wide association study (MWAS) in subjects with self‐reported beta‐lactam allergic reactions using the twinsUK cohort

Caballero MR - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Building confidence in the basophil activation test: Standardization and external quality assurance ‐ an EAACI task force

Pascal M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

Good safety profile, efficacy and few withdrawals during oral immunotherapy with characterised GMP peanut protein in a real‐world setting

Clark A - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved